Compile Data Set for Download or QSAR
Report error Found 12 Enz. Inhib. hit(s) with all data for entry = 8993
TargetGag-Pol polyprotein(HIV-1)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM434878(US10583140, Example 1 | ((1aR,2S,5R,5aS,6S,8aS,9R,...)
Affinity DataEC50:  7nMAssay Description:For the Jurkat HIV Latency assay, compounds are dissolved and titrated in DMSO and diluted 100-fold in assay medium (RPMI-1640 containing 10% fetal b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2020
Entry Details Article
Go to US Patent

TargetGag-Pol polyprotein(HIV-1)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM434941(US10583140, Example 2 | ((1aR,2S,5R,5aS,6S,8aS,9R,...)
Affinity DataEC50:  22nMAssay Description:For the Jurkat HIV Latency assay, compounds are dissolved and titrated in DMSO and diluted 100-fold in assay medium (RPMI-1640 containing 10% fetal b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2020
Entry Details Article
Go to US Patent

TargetGag-Pol polyprotein(HIV-1)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM434942(US10583140, Example 3 | (1aR,2S,5R,5aS,6S,8aS,9R,1...)
Affinity DataEC50:  1.11E+3nMAssay Description:For the Jurkat HIV Latency assay, compounds are dissolved and titrated in DMSO and diluted 100-fold in assay medium (RPMI-1640 containing 10% fetal b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2020
Entry Details Article
Go to US Patent

TargetGag-Pol polyprotein(HIV-1)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM434943(US10583140, Example 4 | (1aR,2S,5R,5aS,8aS,9R,10aR...)
Affinity DataEC50:  4.94E+3nMAssay Description:For the Jurkat HIV Latency assay, compounds are dissolved and titrated in DMSO and diluted 100-fold in assay medium (RPMI-1640 containing 10% fetal b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2020
Entry Details Article
Go to US Patent

TargetGag-Pol polyprotein(HIV-1)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM434945(US10583140, Example 5 | ((1aR,2S,5R,5aR,6S,8aS,9R,...)
Affinity DataEC50:  616nMAssay Description:For the Jurkat HIV Latency assay, compounds are dissolved and titrated in DMSO and diluted 100-fold in assay medium (RPMI-1640 containing 10% fetal b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2020
Entry Details Article
Go to US Patent

TargetGag-Pol polyprotein(HIV-1)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM434946(US10583140, Example 6 | ((1aR,2S,5R,5aR,6S,8aS,9R,...)
Affinity DataEC50:  3.68E+3nMAssay Description:For the Jurkat HIV Latency assay, compounds are dissolved and titrated in DMSO and diluted 100-fold in assay medium (RPMI-1640 containing 10% fetal b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2020
Entry Details Article
Go to US Patent

TargetGag-Pol polyprotein(HIV-1)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM434947(US10583140, Example 7 | ((1aR,2S,5R,5aR,6S,8aS,9R,...)
Affinity DataEC50:  1.05E+3nMAssay Description:For the Jurkat HIV Latency assay, compounds are dissolved and titrated in DMSO and diluted 100-fold in assay medium (RPMI-1640 containing 10% fetal b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2020
Entry Details Article
Go to US Patent

TargetGag-Pol polyprotein(HIV-1)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM434948(US10583140, Example 8 | ((1aR,2S,5R,5aR,6S,8aS,9R,...)
Affinity DataEC50:  4.33E+3nMAssay Description:For the Jurkat HIV Latency assay, compounds are dissolved and titrated in DMSO and diluted 100-fold in assay medium (RPMI-1640 containing 10% fetal b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2020
Entry Details Article
Go to US Patent

TargetGag-Pol polyprotein(HIV-1)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM434949(US10583140, Example 9 | ((1aR,2S,5R,5aR,6S,8aS,9R,...)
Affinity DataEC50:  5.00E+4nMAssay Description:For the Jurkat HIV Latency assay, compounds are dissolved and titrated in DMSO and diluted 100-fold in assay medium (RPMI-1640 containing 10% fetal b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2020
Entry Details Article
Go to US Patent

TargetGag-Pol polyprotein(HIV-1)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM434950(US10583140, Example 10 | ((1aR,2S,5R,5aR,6S,8aS,9R...)
Affinity DataEC50:  278nMAssay Description:For the Jurkat HIV Latency assay, compounds are dissolved and titrated in DMSO and diluted 100-fold in assay medium (RPMI-1640 containing 10% fetal b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2020
Entry Details Article
Go to US Patent

TargetGag-Pol polyprotein(HIV-1)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM434951(US10583140, Example 11 | (1aR,2S,5R,5aS,6S,8aS,9R,...)
Affinity DataEC50:  3.50E+3nMAssay Description:For the Jurkat HIV Latency assay, compounds are dissolved and titrated in DMSO and diluted 100-fold in assay medium (RPMI-1640 containing 10% fetal b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2020
Entry Details Article
Go to US Patent

TargetGag-Pol polyprotein(HIV-1)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM434952(US10583140, Example 12 | (1aR,2S,5R,5aR,6S,8aS,9R,...)
Affinity DataEC50:  5.17E+3nMAssay Description:For the Jurkat HIV Latency assay, compounds are dissolved and titrated in DMSO and diluted 100-fold in assay medium (RPMI-1640 containing 10% fetal b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2020
Entry Details Article
Go to US Patent